Cns Pharmaceuticals Inc (CNSP) Stock Price, Quote & News

Company Profile

CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, develops anti-cancer drug candidates for the treatment of brain and central nervous system (CNS) tumors. The company's drug candidates include TPI 287 and Berubicin, which are in Phase 2 clinical trial for the treatment of glioblastoma and other CNS malignancies. It has license agreement with Cortice Biosciences, Inc. The company was incorporated in 2017 and is headquartered in Houston, Texas.

Industry: Biotechnology

Sector: Healthcare

Phone: 800-946-9185

Website: www.cnspharma.com

Address:

2100 West Loop South, Suite 900, Houston, United States

Vikingsstrade Oct. 3 at 5:55 PM

$IMNN $PC $GBIO $CNSP Merger news on NITO and it barely has 3 million market cap. If people find this, short sellers could get hurt alot on NITO. Small caps have been dead for a while, but NITO gives me hope that short sellers finally get what they deserve!

0 · Reply

kl7777 Oct. 3 at 1:53 PM

$CNSP More should buy and hold 'til $20.

0 · Reply

ClarityOfPurpose Oct. 3 at 12:55 PM

$CNSP They recently had this to say: “commencing a Phase 2 study for the treatment of GBM in the first half of 2026”. No current clinical treatment activity.

0 · Reply

S2K_TP Oct. 3 at 7:57 AM

$CNSP on watch 👀

0 · Reply

MoonCowBoy Oct. 2 at 11:53 PM

$CHPT $PC $GBIO $CNSP |

0 · Reply

1Spartantrade1 Oct. 2 at 7:03 PM

Massive merger news 3 days ago on NITO! NITO has a low share count like TTNP (BTTC) does. TTNP ran 400% today. Can NITO also run 400%? Make sure to take profits. Lets see if NITO halts up today when people realize. $CNSP $USBC $OTLY $MEGL .

0 · Reply

kl7777 Oct. 2 at 6:58 PM

$CNSP Not many posts here again. We need to have a green day today. Buy a share at market price.

0 · Reply

1Spartantrade1 Oct. 2 at 6:29 PM

0 · Reply

kl7777 Oct. 2 at 12:31 PM

$CNSP Buy even few shares at high market/limit asks to move the price up and hold 'til $20.

0 · Reply

kl7777 Oct. 1 at 4:04 PM

$CNSP No update on price since 10:59am. This stock was over $20 few months ago. Buy even one share at high market asks to move the price up.

0 · Reply

CNS Pharmaceuticals to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Aug 15, 2025, 8:05 AM EDT - 7 weeks ago

CNS Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 14, 2025, 9:15 AM EDT - 7 weeks ago

CNS Pharmaceuticals to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech

Jul 22, 2025, 8:45 AM EDT - 2 months ago

CNS Pharmaceuticals to Participate in the Virtual Investor "What's Your Story" Summer Spotlight On-Demand Conference

Jul 18, 2025, 8:00 AM EDT - 2 months ago

CNS Pharmaceuticals Announces Reverse Stock Split

Jul 9, 2025, 9:32 AM EDT - 3 months ago

CNS Pharmaceuticals Participates in Virtual Investor CEO Connect Segment

Jun 24, 2025, 9:15 AM EDT - 3 months ago

CNS Pharmaceuticals Announces Virtual Investor KOL Connect Segment Discussing Glioblastoma Multiforme (GBM) and Lead Product Candidate TPI 287

Jun 5, 2025, 8:05 AM EDT - 4 months ago

CNS Pharmaceuticals' Chief Medical Officer, Sandra Silberman, MD, PhD to Present at the 2025 Brain Tumor Biotech Summit

May 16, 2025, 8:05 AM EDT - 5 months ago

CNS Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 13, 2025, 9:35 AM EDT - 5 months ago

CNS Pharmaceuticals Announces Pricing of $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules

May 13, 2025, 7:00 AM EDT - 5 months ago

CNS Pharmaceuticals Acquires Orphan Drug Designation for Novel, Late Stage Abeotaxane, TPI 287

Apr 1, 2025, 8:05 AM EDT - 6 months ago

CNS Pharmaceuticals Reports Full Year 2024 Financial Results

Mar 25, 2025, 12:05 PM EDT - 6 months ago

CNS Pharma's Cancer Drug Misses Survival Goal But May Offer Fewer Side Effects

Mar 25, 2025, 8:00 AM EDT - 6 months ago

CNS Pharmaceuticals Announces Primary Analysis of Berubicin in Second Line Treatment of Glioblastoma Multiforme

Feb 26, 2025, 9:05 AM EST - 7 months ago

CNS Pharmaceuticals Provides Update on Current Cash Position and NASDAQ Listing

Feb 20, 2025, 9:00 AM EST - 8 months ago

CNS Pharmaceuticals to Present at the 18th Annual European Life Sciences CEO Forum

Feb 19, 2025, 9:00 AM EST - 8 months ago

CNS Pharmaceuticals, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

Feb 18, 2025, 9:00 AM EST - 8 months ago

CNS Pharmaceuticals to Present at 6th Glioblastoma Drug Development Summit

Feb 10, 2025, 8:00 AM EST - 8 months ago

CNS Pharmaceuticals to Present at the BIO CEO & Investor Conference

Dec 5, 2024, 9:10 AM EST - 10 months ago

CNS Pharmaceuticals to Host Virtual Analyst & Investor Day on December 11, 2024

Nov 25, 2024, 9:00 AM EST - 11 months ago

CNS Pharmaceuticals Presents Update from Ongoing Potentially Pivotal Study of Berubicin Compared with Lomustine in Adult Patients with Recurrent GBM (WHO Grade IV) After Failure of Standard First Line Therapy

Nov 18, 2024, 8:55 AM EST - 11 months ago

CNS Pharmaceuticals Announces Abstract Accepted for Poster Presentation at the 29th Annual Meeting of the Society for Neuro-Oncology (SNO 2024)

Nov 15, 2024, 9:10 AM EST - 11 months ago

CNS Pharmaceuticals Reports Third Quarter 2024 Financial Results

Nov 4, 2024, 9:15 AM EST - 11 months ago

CNS Pharmaceuticals Announces Virtual Investor KOL Connect Segment

Nov 1, 2024, 9:00 AM EDT - 1 year ago

CNS Pharmaceuticals Granted Exception by Nasdaq to Regain Compliance with Minimum Bid Price Requirement

Oct 23, 2024, 2:50 PM EDT - 1 year ago

CNS Pharmaceuticals Announces Pricing of $3 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules

Oct 10, 2024, 9:00 AM EDT - 1 year ago

CNS Pharmaceuticals Participates in Virtual Investor KOL Connect Segment

Oct 8, 2024, 9:15 AM EDT - 1 year ago

CNS Pharmaceuticals to Participate in the 2024 Healthcare Virtual Summit Presented by Maxim Group LLC

Sep 23, 2024, 9:00 AM EDT - 1 year ago

CNS Pharmaceuticals to Present at the 24th Annual Biotech in Europe Forum

Sep 12, 2024, 9:00 AM EDT - 1 year ago

CNS Pharmaceuticals Regains Compliance with Nasdaq Equity Requirement

Sep 4, 2024, 9:05 AM EDT - 1 year ago

CNS Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Sep 3, 2024, 8:00 AM EDT - 1 year ago

IBN Announces Latest Episode of The BioMedWire Podcast featuring John Climaco, CEO of CNS Pharmaceuticals Inc.

Aug 27, 2024, 9:10 AM EDT - 1 year ago

CNS Pharmaceuticals to Participate in at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar

Aug 22, 2024, 9:15 AM EDT - 1 year ago

CNS Pharmaceuticals to Participate in Virtual Investor CEO Connect Segment

Aug 15, 2024, 8:00 AM EDT - 1 year ago

CNS Pharmaceuticals Reports Second Quarter 2024 Financial Results

Jul 30, 2024, 7:00 AM EDT - 1 year ago

CNS Pharmaceuticals Expands Pipeline with In-License of Late Stage, Novel Potential Blood Brain Barrier Permeable Abeotaxane for Treatment of Brain Malignancies

Jul 25, 2024, 9:05 AM EDT - 1 year ago

CNS Pharmaceuticals Announces Acceptance of Abstract for Poster Presentation at the 2024 SNO/ASCO CNS Cancer Conference

Jul 16, 2024, 9:15 AM EDT - 1 year ago

CNS Pharmaceuticals to Participate in the Virtual Investor Closing Bell Series

Jul 3, 2024, 11:10 AM EDT - 1 year ago

CNS Pharmaceuticals Announces Pricing of Registered Direct Offering and Concurrent Private Placement

May 20, 2024, 8:30 AM EDT - 1 year ago

CNS Pharmaceuticals to Present at Alliance Global Partner's 2024 Healthcare Company Showcase

May 16, 2024, 7:45 AM EDT - 1 year ago

CNS Pharmaceuticals Reports First Quarter 2024 Financial Results

Apr 23, 2024, 9:00 AM EDT - 1 year ago

CNS Pharmaceuticals to Present at the LSX World Congress 2024

Apr 22, 2024, 10:15 AM EDT - 1 year ago

CNS Pharmaceuticals to Participate in the Virtual Investor Lunch Break: The CNSP Opportunity

Apr 1, 2024, 5:00 PM EDT - 1 year ago

CNS Pharmaceuticals Reports Full Year 2023 Financial Results and Highlights Recent Corporate and Clinical Achievements

Apr 1, 2024, 9:05 AM EDT - 1 year ago

CNS Pharmaceuticals to Present at Two Investor Conferences in April

Feb 9, 2024, 8:35 AM EST - 1 year ago

Top 5 Health Care Stocks That Are Preparing To Pump In February

GILD REVB ZLAB

Jan 29, 2024, 9:00 PM EST - 1 year ago

CNS Pharmaceuticals Announces Pricing of $4.0 Million Public Offering

Jan 18, 2024, 8:45 AM EST - 1 year ago

Biotech Commercialization Leader, Amy Mahery, to Join CNS Pharmaceuticals Board of Directors

Jan 17, 2024, 8:45 AM EST - 1 year ago

CNS Pharmaceuticals Achieves Completion of Planned Enrollment in Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme (GBM)

Dec 18, 2023, 8:35 AM EST - 1 year ago

CNS Pharmaceuticals Announces Successful Interim Analysis of Efficacy and Safety Data in Potentially Pivotal Study of Berubicin

Vikingsstrade Oct. 3 at 5:55 PM

0 · Reply

kl7777 Oct. 3 at 1:53 PM

$CNSP More should buy and hold 'til $20.

0 · Reply

ClarityOfPurpose Oct. 3 at 12:55 PM

$CNSP They recently had this to say: “commencing a Phase 2 study for the treatment of GBM in the first half of 2026”. No current clinical treatment activity.

0 · Reply

S2K_TP Oct. 3 at 7:57 AM

$CNSP on watch 👀

0 · Reply

MoonCowBoy Oct. 2 at 11:53 PM

$CHPT $PC $GBIO $CNSP |

0 · Reply

1Spartantrade1 Oct. 2 at 7:03 PM

0 · Reply

kl7777 Oct. 2 at 6:58 PM

$CNSP Not many posts here again. We need to have a green day today. Buy a share at market price.

0 · Reply

1Spartantrade1 Oct. 2 at 6:29 PM

0 · Reply

kl7777 Oct. 2 at 12:31 PM

$CNSP Buy even few shares at high market/limit asks to move the price up and hold 'til $20.

0 · Reply

kl7777 Oct. 1 at 4:04 PM

$CNSP No update on price since 10:59am. This stock was over $20 few months ago. Buy even one share at high market asks to move the price up.

0 · Reply

kl7777 Oct. 1 at 2:54 PM

$CNSP Whether you like this company or not, more should buy even few shares at market asks to move the price up. Buy and hold.

0 · Reply

spekul8or Sep. 30 at 7:27 PM

$CNSP We're so close. I can taste it!

0 · Reply

NetworkNewsWire Sep. 30 at 5:21 PM

Scorpion Venom Shows Promise in Brain Tumor Treatment $CNSP https://ibn.fm/R677l #biomedstocks #Treatments

0 · Reply

Zig2Zag Sep. 30 at 4:55 PM

$CNSP No volume happening here

0 · Reply

Tom__Brady Sep. 30 at 1:26 AM

$CNSP DO NOT fall for “investment” into this SCAM of a company. Since November 2022 this garbage company has completed FOUR reverse stock splits. November 29, 2022 - 1 for 30 June 5, 2024 - 1 for 50 Feb 21, 2025 - 1 for 50 Jul 22, 2025 - 1 for 15 WOW! That is an incredible destruction of shareholder value. If you owned 100,000 shares in November 2022, you would effectively own ZERO shares today. Failed Berubicin trial, now another “registrational” years long trial. Climaco is a fraud and a scam artist. He will continue to dilute in order to pay himself his $1,000,000+ salary (with stock options) if he can even find anyone left to invest at this point. You’ve been warned!

0 · Reply

kl7777 Sep. 29 at 5:16 PM

$CNSP A new post uploaded on company's X account, explaining their good network and research skill.

1 · Reply

MoonCowBoy Sep. 26 at 9:44 PM

retail running GYRO now! the GYRO Float only 600k could squeeze hard wow $CNSP $TWG $IVF $GVH //

0 · Reply

spekul8or Sep. 26 at 8:14 PM

$CNSP looking good here ladies. Pushing through 9 AH

0 · Reply

kl7777 Sep. 26 at 7:20 PM

$CNSP No update on price since 2:16pm. Someone needs to buy even at high asks. Buying a few shouldn't make that difference.

0 · Reply

isaacwilliams33 Sep. 25 at 10:35 PM

$CNSP

0 · Reply

spekul8or Sep. 25 at 5:09 PM

$CNSP

0 · Reply

JGroove Sep. 25 at 3:59 PM

$CNSP in queue

0 · Reply

Market Cap	5.10M
Revenue (ttm)	0.00
Net Income (ttm)	-14.86M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	7,900
Avg Vol	55,660
Day's Range	N/A - N/A
Shares Out	575,000.00
Stochastic %K	96%
Beta	2.68
Analysts	Strong Sell
Price Target	$20.00